Saturday 17 October 2026
Export ABSI’s income statement to Excel — free account
Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.25
0.63
−7.09%
Follow ABSI
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 2 | 3 | 3 | 3 |
Altman Z-Score |
— | — | — | 3.54 | 0.67 | 1.80 | 0.62 | 5.50 |
P/S ratio |
— | 70.08 | 70.08 | 85.20 | 35.72 | 59.39 | 63.70 | 170.48 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (4.11) | 3.61 | 7.43 | 4.14 | (2.42) | (2.52) | (1.90) |
P/Operating CF |
— | (26.29) | (26.29) | (23.85) | (11.06) | (22.76) | (17.03) | (16.36) |
Beneish M-Score |
— | — | 0.47 | (2.66) | (2.90) | (3.24) | — | — |
P/B ratio |
— | 0.00 | 0.00 | 1.11 | 0.75 | 1.93 | 1.61 | 2.52 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.41 | 1.02 | 2.65 | 2.15 | 3.23 |
EV/Sales |
— | 78.96 | 78.96 | 31.60 | 6.53 | 40.86 | 36.27 | 119.28 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (15.89) | (15.89) | (2.49) | (0.46) | (3.61) | (2.27) | (3.59) |
EV/FCF |
— | (8.13) | (8.13) | (1.53) | (0.39) | (3.58) | (2.29) | (3.60) |
Quick Ratio |
— | 3.84 | 7.08 | 7.81 | 5.98 | 3.93 | 4.48 | 6.34 |
Current Ratio |
— | 3.94 | 7.25 | 8.07 | 6.17 | 4.08 | 4.67 | 6.57 |
Net Debt/EBITDA |
— | 1.59 | 5.10 | 3.74 | 1.79 | 1.32 | 1.30 | 1.32 |
Debt/Assets |
0.00% | 20.02% | 8.82% | 1.58% | 3.64% | 3.64% | 1.87% | 0.40% |
Debt/Equity |
— | 0.34 | 0.12 | 0.02 | 0.04 | 0.04 | 0.02 | 0.00 |
Asset Turnover |
— | 0.21 | 0.09 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
Operating CF/Net income |
— | 0.25 | 0.22 | 0.59 | 0.78 | 0.58 | 0.70 | 0.81 |
Capex/Depreciation |
— | (2.22) | (1.92) | (5.72) | (1.23) | (0.02) | 0.04 | 0.02 |
Interest Coverage |
— | (23.38) | (20.98) | (21.92) | (109.83) | (114.37) | (192.72) | (575.68) |
| — | 36.56% | 75.76% | (74.63%) | (32.76%) | (49.08%) | (58.04%) | (62.50%) | |
| — | (245.19%) | (91.58%) | (40.11%) | (28.08%) | (41.08%) | (47.86%) | (53.59%) | |
ROIC |
— | (162.00%) | (168.01%) | (42.83%) | (62.56%) | (102.78%) | (124.30%) | (163.37%) |
Return on Tangible Assets |
— | (177.09%) | (68.66%) | (35.44%) | (50.12%) | (83.54%) | (76.75%) | (78.00%) |
Average Days of Receivables |
— | 39.34 | 121.72 | 108.77 | 98.44 | 139.73 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 209.27% | 239.50% | 932.37% | 1,025.02% | 840.63% | 1,408.45% | 2,907.79% |
Selling, General and Administrative Expense of Revenue |
— | 171.02% | 115.10% | 601.84% | 705.62% | 661.63% | 797.84% | 1,252.07% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.18 | 0.23 | 0.22 | 0.21 | 0.19 |
Share Based Compensation of Revenue |
— | 2.04% | 8.79% | 221.83% | 218.20% | 199.65% | 429.03% | 654.32% |
Graham Net Nets |
— | (0.28) | (0.28) | 0.52 | 0.68 | 0.23 | 0.34 | 0.26 |
Graham Number |
— | 0.00 | 10.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (16.63%) | (16.63%) | (44.46%) | (51.33%) | (32.52%) | (35.50%) | (24.36%) |
Free Cash Flow Yield |
— | (13.85%) | (13.85%) | (24.21%) | (47.43%) | (19.21%) | (24.88%) | (19.42%) |
Revenue per Share |
— | 0.14 | 0.31 | 0.10 | 0.06 | 0.06 | 0.04 | 0.02 |
Operating CF per Share |
— | (0.40) | (0.71) | (1.22) | (0.90) | (0.70) | (0.66) | (0.68) |
Capex per Share |
— | (0.07) | (0.14) | (0.77) | (0.18) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.47) | (0.85) | (1.99) | (1.07) | (0.71) | (0.65) | (0.68) |
Cash per Share |
— | 0.86 | 4.51 | 5.30 | 1.98 | 1.24 | 1.16 | 1.05 |
Shareholders Equity per Share |
— | 0.76 | 4.32 | 7.37 | 3.02 | 1.91 | 1.62 | 1.39 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.76 | 4.32 | 7.37 | 3.02 | 1.91 | 1.62 | 1.39 |
Free Cash Flow |
— | (7.12) | (13.14) | (98.64) | (97.38) | (65.24) | (71.87) | (92.72) |
Working Capital |
— | 10.18 | 63.14 | 239.22 | 156.59 | 91.02 | 105.18 | 126.81 |
Capital Expenditures |
— | (1.09) | (2.17) | (38.05) | (16.04) | (0.61) | 0.54 | 0.21 |
Net Current Asset Value |
— | 5.78 | 51.67 | 212.99 | 140.27 | 79.46 | 99.36 | 122.73 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.53 | 0.45 | 7.96 | 2.79 | 0.11 | (0.12) | (0.07) |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.15 | 0.13 | 0.13 | 0.25 | 0.86 | 0.46 | 0.56 |
Cash ROIC |
— | (24.91%) | (9.08%) | (15.51%) | (20.92%) | (21.90%) | (23.07%) | (27.71%) |
Accounts Receivable Turnover |
— | 2.27 | 5.26 | 3.17 | 3.86 | 3.06 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.91 | 0.91 | 1.51 | 1.49 | 1.87 | — | — |
Average Payables |
— | 1.19 | 1.19 | 5.25 | 5.40 | 1.96 | 5.98 | 14.90 |
Average Assets |
— | 9.74 | 54.02 | 257.38 | 373.60 | 269.15 | 215.45 | 214.95 |
Average Common Equity |
— | (65.29) | (65.29) | 138.34 | 320.26 | 225.29 | 177.65 | 184.29 |
Columns are period end dates